USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2022 TO 9/30/2023

DEPT PI		AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
How ard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-001	New	5/12/2023	\$0
How ard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-002	Continuation	9/30/2023	\$10,800
lmran,	Hamayun	NIH	CHOP w orkload Intensity U10CA180886 NCTN Operations grant.	A21-0184-004	Continuation	9/30/2023	\$11,000
lmran,	Hamayun	NIH	PER CASE REIMBURSEMENT NCTN Operations Grant U10CA180886	A21-0185-003	Continuation	9/30/2023	\$36,876
lmran,	Hamayun	PHI	CHILDREN'S ONCOLOGY GROUP PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955Per Case Reimbursement (PCR)	A21-0228-002	Continuation	9/30/2023	\$8,720
lmran,	Hamayun	PHI	A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPXo0444454(M)10.7 (-)Xsemt (a))-6.5 (r)-42 91 /390625 02351ti	Ted &(1)190.551((1)a 97 24 4 /11 /4626 8433;2-86	08224.3756255 25/10 b/ /P Add 8 86	120NE6442 (\$.) -18 558 (15)-166.T5d0Y(

USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2022 TO 9/30/2023

DEPT PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Persing, Brian	NIH	A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer	A21-0037-002	Continuation	9/30/2023	\$2,900
Prodduturv Pranith	a SGI	SGNTUC-016 HER2+	A20-0107-004	Continuation	9/30/2023	\$21,612